Studies have shown that using small molecule EP4 antagonists, such as ONO-AE3-208 and AH23848, or silencing the EP4 gene, can significantly reduce the metastatic potential of RCC in preclinical models. This evidence concerns the gene PTGER4 and renal cell carcinoma.